HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ERW1041E

a transglutaminase 2 inhibitor

Also Known As:

(2-((3-bromo-4,5-dihydro-isoxazol-5-ylmethyl)-carbamoyl)-pyrrolidine-1-carboxylic acid quinolin-3-ylmethyl ester

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Isoxazoles: 155
      - ERW1041E: 3
  - Pyrrolidines: 115
    - ERW1041E: 3
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - ERW1041E: 3

Experts

1.	Bol, John G J M: 1 article (01/2018)
2.	Brevé, John J P: 1 article (01/2018)
3.	Chrobok, Navina L: 1 article (01/2018)
4.	Drukarch, Benjamin: 1 article (01/2018)
5.	El Alaoui, Said: 1 article (01/2018)
6.	Frangogiannis, Nikolaos G: 1 article (01/2018)
7.	Fujikura, Kana: 1 article (01/2018)
8.	Garcia, Mario J: 1 article (01/2018)
9.	Jongenelen, Cornelis A: 1 article (01/2018)
10.	Palanski, Brad A: 1 article (01/2018)

Related Diseases

1.	Hypoxia (Hypoxemia) 11/01/2017 - "Pharmacological inhibition of TG2 activity with ERW1041E significantly reduced hypoxia-induced cross-linking activity and synthesis of collagen 1 and α-smooth muscle actin in both the in vivo and in vitro studies. "
2.	Left Ventricular Dysfunction 01/01/2018 - "tTG inhibition through administration of the selective small molecule tTG inhibitor ERW1041E attenuated left ventricular diastolic dysfunction and reduced cardiomyocyte hypertrophy and interstitial fibrosis in the pressure-overloaded heart, without affecting chamber dimensions and ejection fraction. "
3.	Inflammation (Inflammations) 01/01/2018 - "We found, that ERW1041E but not BJJF078 resulted in reduced EAE disease motor-symptoms while neither caused apparent changes in pathology (cellular influx), Transglutaminase activity or expression of inflammation related markers in the spinal cord, compared to vehicle treated controls. "
4.	Hypertrophy 01/01/2018 - "tTG inhibition through administration of the selective small molecule tTG inhibitor ERW1041E attenuated left ventricular diastolic dysfunction and reduced cardiomyocyte hypertrophy and interstitial fibrosis in the pressure-overloaded heart, without affecting chamber dimensions and ejection fraction. "
5.	Fibrosis (Cirrhosis) 01/01/2018 - "tTG inhibition through administration of the selective small molecule tTG inhibitor ERW1041E attenuated left ventricular diastolic dysfunction and reduced cardiomyocyte hypertrophy and interstitial fibrosis in the pressure-overloaded heart, without affecting chamber dimensions and ejection fraction. "

Related Drugs and Biologics

1.	Collagen
2.	Transglutaminases
3.	BJJF078